 Design and Methods We conducted a single-center, retrospective study involving 499 acute myeloid leukemia patients, aged 18-92 years, all evaluated between 1978 and 2007. Of those 499 patients, 400 received curative treatment and 203 received cytarabine consolidation. The latter were divided into three groups: low-dose receiving 1.5 gm2 of i.v. cytarabine, every 12 h, on 3 alternate days, for up to 4 cycles; medium-high-dose 45.45 gthe median doseby the end of the cycles; and very-high-dose 45.45 g by the end of the cycles. 